Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disability Evaluation Clear all
Completed Not applicable Interventional

H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation

NCT02699814
View directory record Official record
Conditions
Developmental Delay, Mental Health Disorder
Interventions
H3 Services
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 16 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 7, 2026, 7:21 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

NCT00754052
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
11 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 7, 2026, 7:21 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Telehealth Services on Mental Health Outcomes for People With Intellectual and Developmental Disabilities

NCT05336955
View directory record Official record
Conditions
Mental Health Conditions, Developmental Disability
Interventions
Intake and quarterly assessment:, Consultation & coping skills coaching:, 24-hour urgent crisis response and intervention:, Service linkages, referrals, outreach, & training:
Other
Lead sponsor
University of New Hampshire
Other
Eligibility
12 Years to 45 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 7, 2026, 7:21 AM EDT
Completed Phase 2Phase 3 Interventional

A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

NCT03231878
View directory record Official record
Conditions
Adrenoleukodystrophy
Interventions
MIN-102, Placebos
Drug
Lead sponsor
Minoryx Therapeutics, S.L.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sight and Hearing Investigation Into Effects on Delirium

NCT06176625
View directory record Official record
Conditions
Hearing Loss, Hearing Loss, Age-Related, Hearing Disability, Delirium, Delirium in Old Age, Delirium of Mixed Origin, Delirium With Dementia, Delirium on Emergence, Delirium, Cause Unknown, Delirium Superimposed on Dementia, Delirium Confusional State, Delirium;Non Alcoholic, Hearing Loss, Bilateral, Hearing Loss, Sensorineural, Hearing Loss, Functional, Hearing Loss, High-Frequency, Hearing
Interventions
Communication Signage, Amplifier Use
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
1,543 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 7, 2026, 7:21 AM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

NCT05238324
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718910
View directory record Official record
Conditions
DDX3X, Mental Retardation, X-linked 102, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

NCT00892580
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
STX209
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 7, 2026, 7:21 AM EDT
Terminated Phase 2 Interventional

An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome

NCT01013480
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Arbaclofen
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
6 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Sep 7, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Computerized Template Entry for Compensation and Pension (C&P) Examinations

NCT00988546
View directory record Official record
Conditions
Joint Diseases
Interventions
Computer based template for exam documentation, Dictation for exam documentation
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2009 · Synced Sep 7, 2026, 7:21 AM EDT
Completed Not applicable Interventional

RETAINWORKS Impact Evaluation

NCT05167981
View directory record Official record
Conditions
Disability
Interventions
RETAINWORKS
Other
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Topeka, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 7, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

NCT01357239
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Sacramento, California • Decatur, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 7, 2026, 7:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

RASopathy Biorepository

NCT04395495
View directory record Official record
Conditions
RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2065
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders

NCT02836405
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational

Evaluation of Patients With Unresolved Chromosome Abnormalities

NCT00001639
View directory record Official record
Conditions
Abnormalities, Failure to Thrive, Mental Retardation, Microcephaly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 7:21 AM EDT
Recruiting No phase listed Observational

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718936
View directory record Official record
Conditions
ADNP, Helsmoortel-Van Der Aa Syndrome, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years and older
Enrollment
30 participants
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder

NCT01452061
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit/Hyperactivity Disorder, Developmental Delay
Interventions
Not listed
Lead sponsor
Thomas W. Frazier, Ph.D
Other
Eligibility
1 Year to 12 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 7, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Living Well With a Disability Curriculum Adaptation Evaluation Plan

NCT03447119
View directory record Official record
Conditions
Health Education, Community Health Services, Health Services for Persons With Disabilities, Developmental Disabilities
Interventions
Living Well with a Disability
Behavioral
Lead sponsor
Georgia Southern University
Other
Eligibility
3 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Springfield, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational

Tube Feeding Tolerance After Switch to Peptide Based Formula in Children With Developmental Delay

NCT02912065
View directory record Official record
Conditions
Developmental Disabilities, Feeding Disorder
Interventions
Not listed
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
13 Months to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 7, 2026, 7:21 AM EDT
Terminated No phase listed Observational

Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

NCT02204904
View directory record Official record
Conditions
X-Linked Adrenoleukodystrophy (X-ALD), Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD)
Interventions
Allo-HSCT
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 7, 2026, 7:21 AM EDT
Completed No phase listed Observational

Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

NCT01555346
View directory record Official record
Conditions
Down Syndrome, Fetal Aneuploidy
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Mobile, Alabama • Tucson, Arizona • Campbell, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 7, 2026, 7:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

NCT03500627
View directory record Official record
Conditions
Healthy
Interventions
OP-101
Drug
Lead sponsor
Orpheris, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 7, 2026, 7:21 AM EDT
Active, not recruiting Phase 3 Interventional

RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)

NCT07236606
View directory record Official record
Conditions
MPS II, Hunter Syndrome (MPS II)
Interventions
RGX-121-3102
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
4 Months to 5 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 7, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Evaluation of Contrast Sensitivity and Disability Glare in Refractive Surgery, a Sub-Study of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

NCT00413868
View directory record Official record
Conditions
Myopia
Interventions
LASIK, PRK, Small target contrast sensitivity and disability glare
Procedure · Behavioral
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Sep 7, 2026, 7:21 AM EDT